RT Journal Article
SR Electronic
T1 Projecting the seasonality of endemic COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.26.22269905
DO 10.1101/2022.01.26.22269905
A1 Jeffrey P. Townsend
A1 April D. Lamb
A1 Hayley B. Hassler
A1 Pratha Sah
A1 Aia Alvarez Nishio
A1 Cameron Nguyen
A1 Alexandra D. Tew
A1 Alison P. Galvani
A1 Alex Dornburg
YR 2022
UL http://medrxiv.org/content/early/2022/10/07/2022.01.26.22269905.abstract
AB Importance Successive waves of infection by SARS-CoV-2 have left little doubt that COVID-19 will transition to an endemic disease, yet the future seasonality of COVID-19 remains one of its most consequential unknowns. Foreknowledge of spatiotemporal surges would have immediate and long-term consequences for medical and public health decision-making.Objective To estimate the impending endemic seasonality of COVID-19 in temperate population centers via a phylogenetic ancestral and descendent states approach that leverages long-term data on the incidence of circulating coronaviruses.Design We performed a comparative evolutionary analysis on literature-based monthly verified cases of HCoV-NL63, HCoV-229E, HCoV-HKU1, and HCoV-OC43 infection within populations across the Northern Hemisphere. Ancestral and descendent states analyses on human-infecting coronaviruses provided projections of the impending seasonality of endemic COVID-19.Setting Quantitative projections of the endemic seasonality of COVID-19 were based on human endemic coronavirus infection incidence data from New York City (USA); Denver (USA); Tampere (Finland); Trøndelag (Norway); Gothenburg (Sweden); Stockholm (Sweden); Amsterdam (Netherlands); Beijing (China); South Korea (Nationwide); Yamagata (Japan); Hong Kong; Nakon Si Thammarat (Thailand); Guangzhou (China); and Sarlahi (Nepal).Main Outcome(s) and Measure(s) The primary projection was the monthly relative frequency of SARS-CoV-2 infections in each geographic locale. Four secondary outcomes consisted of empirical monthly relative frequencies of the endemic human-infecting coronaviruses HCoV-NL63, -229E, -HKU1, and -OC43.Results We project asynchronous surges of SARS-CoV-2 across locales in the Northern Hemisphere. In New York City, SARS-CoV-2 incidence is projected in late fall and winter months (Nov.–Jan.), In Tampere, Finland; Yamagata, Japan; and Sarlahi, Nepal incidence peaks in February. Gothenburg and Stockholm in Sweden reach peak incidence between November and February. Guangzhou, China; and South Korea. In Denver, incidence peaks in early Spring (Mar.). In Amsterdam, incidence rises in late fall (Dec.), and declines in late spring (Apr.). In Hong Kong, the projected apex of infection is in late fall (Nov.–Dec.), yet variation in incidence is muted across other seasons. Seasonal projections for Nakhon Si Thammarat, Thailand and for Beijing, China are muted compared to other locations.Conclusions and Relevance This knowledge of likely spatiotemporal surges of COVID-19 is fundamental to medical preparedness and expansions of public health interventions that anticipate the impending endemicity of this disease and mitigate COVID-19 transmission. These results provide crucial guidance for adaptive public health responses to this disease, and are vital to the long-term mitigation of COVID-19 transmission.Question Under endemic conditions, what are the projected spatiotemporal seasonal surges of COVID-19?Findings We applied a phylogenetic ancestral and descendent states approach, leveraging long-term data on the incidence of circulating coronaviruses. We found that seasonal surges are expected in or near the winter months; dependent on the specific population center, infections are forecasted to surge in the late fall, winter, or early spring.Meaning Globally, endemic COVID-19 surges should be expected to occur asynchronously, often coincident with local expected surges of other human-infecting respiratory viruses.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNational Science Foundation of the United States of America RAPID 2031204 (JPT and AD), NSF Expeditions CCF 1918784 (JPT and APG), and support from the University of North Carolina, Charlotte to AD.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and materials availability All data, inferred phylogenetic trees, imputed monthly proportions, and code underlying this study are publicly available on Zenodo: DOI:10.5281/zenodo.5274735. https://zenodo.org/record/5274735#.YfGrBRPMIeY